CA2562069A1 - Therapeutic combination for treatment of alzheimers disease - Google Patents

Therapeutic combination for treatment of alzheimers disease Download PDF

Info

Publication number
CA2562069A1
CA2562069A1 CA002562069A CA2562069A CA2562069A1 CA 2562069 A1 CA2562069 A1 CA 2562069A1 CA 002562069 A CA002562069 A CA 002562069A CA 2562069 A CA2562069 A CA 2562069A CA 2562069 A1 CA2562069 A1 CA 2562069A1
Authority
CA
Canada
Prior art keywords
active
pharmaceutically acceptable
disease
alzheimer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002562069A
Other languages
English (en)
French (fr)
Inventor
Gregg H. Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2562069A1 publication Critical patent/CA2562069A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002562069A 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease Abandoned CA2562069A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
US60/562,141 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
CA2562069A1 true CA2562069A1 (en) 2005-10-27

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002562069A Abandoned CA2562069A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Country Status (14)

Country Link
EP (1) EP1737539A1 (https=)
JP (1) JP2007532624A (https=)
KR (1) KR20060133008A (https=)
CN (1) CN1960781A (https=)
AU (1) AU2005232447A1 (https=)
BR (1) BRPI0509881A (https=)
CA (1) CA2562069A1 (https=)
IL (1) IL178120A0 (https=)
MX (1) MXPA06011969A (https=)
NO (1) NO20065196L (https=)
RU (1) RU2006136361A (https=)
TW (1) TW200533341A (https=)
WO (1) WO2005099823A1 (https=)
ZA (1) ZA200608239B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
EP3903767A1 (en) * 2016-02-11 2021-11-03 SigmaThera SAS Igmesine for use in the treatment of neurodegenerative diseases
PL3982956T3 (pl) * 2019-06-14 2024-10-28 Joshua O. Atiba Potrójna kompozycja farmaceutyczna na zakażenie białkowe

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
MXPA04009535A (es) * 2002-04-02 2005-01-25 Janssen Pharmaceutica Nv Terapia con estatina para mejorar el mantenimiento cognoscitivo.
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2004222529A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. INF-beta alone or in combination with other medicaments for treating Alzheimer's disease and demens disorders
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
WO2005099823A1 (en) 2005-10-27
KR20060133008A (ko) 2006-12-22
BRPI0509881A (pt) 2007-10-16
CN1960781A (zh) 2007-05-09
NO20065196L (no) 2007-01-03
TW200533341A (en) 2005-10-16
JP2007532624A (ja) 2007-11-15
AU2005232447A1 (en) 2005-10-27
IL178120A0 (en) 2006-12-31
EP1737539A1 (en) 2007-01-03
MXPA06011969A (es) 2006-12-15
ZA200608239B (en) 2008-06-25
RU2006136361A (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
JP6196225B2 (ja) 糖尿病新規発症低減用組成物
Jelic et al. Treatment of mild cognitive impairment: rationale, present and future strategies
JP2002529500A (ja) ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法
MXPA04012149A (es) El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas.
RU2403039C2 (ru) Лечение биполярных расстройств и сопутствующих симптомов
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
CA2562069A1 (en) Therapeutic combination for treatment of alzheimers disease
EA002526B1 (ru) Применение фанхинона для лечения болезни альцгеймера
Herrmann Cognitive pharmacotherapy of Alzheimer's disease and other dementias
US20220160739A1 (en) Methods for treating subjects with chronic kidney disease
AU2013315383A1 (en) Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy
WO2003032995A1 (en) Rosuvastatin in pre demented states
CA2681185C (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
US6358977B1 (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
EP3461481A1 (en) Methods of maintaining, treating or improving cognitive function
Fernandez et al. The use of methylphenidate in HIV patients: A clinical perspective
EP1438043A2 (en) Method of reducing type 2 diabetes in high risk patients
CA3169026C (en) Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
Singh et al. To the Editor: Huntington_s disease (HD) is an autosomal dominant
WO2006057209A1 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
AU2002347698A1 (en) Rosuvastatin in pre demented states
AU2002362897A1 (en) Method of reducing type 2 diabetes in high risk patients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued